ArticleMalaria journal2026
Ex vivo susceptibility to dihydroartemisinin in Plasmodium falciparum patient isolates from Eastern Rwanda, 2025.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe emergence of artemisinin partial resistance (AR) in Plasmodium falciparum, characterized by mutations in the Plasmodium falciparum Kelch 13 (PfK13) gene and delayed parasite clearance, represents a significant threat to malaria control in Africa. While the Ring-Stage Survival Assay (RSA) is the phenotypic gold standard for AR detection, its technical complexity limits scalability. The Extended Recovery Ring-Stage Survival Assay (eRRSA), utilizing quantitative PCR (qPCR), has been proposed as a more scalable alternative for molecular surveillance.
methodsIn early 2025, 19 clinical P. falciparum isolates were collected and analyzed from the Kirehe district of Rwanda. AR phenotypes were characterized using both ex vivo RSA (72-h microscopy) and eRRSA (120-h qPCR). Parasite genotypes were determined via Sanger sequencing of the PfK13 propeller domain. Statistical analyses, including Spearman correlation and Receiver Operating Characteristic (ROC) curves, were applied to compare assay performance and define resistance thresholds.
resultsNon-synonymous PfK13 mutations were identified in 52.6% (10/19) of isolates, predominantly the validated R561H marker (31.6%). The N490T mutation (2/19) was detected for the first time in Rwanda. RSA-confirmed AR (survival rate >1%) was present in 38.9% of valid assays. The R561H mutation was significantly associated with elevated RSA survival (P=0.02), and the N490T isolates had high survival rates. Two further rare variants, P667S (2/18) and F699C (1/18), did not show elevated survival rates. eRRSA recovery rates correlated with RSA survival (P=0.003, ρ=-0.7); however, eRRSA exhibited moderate diagnostic accuracy (AUC = 0.86). A recovery rate threshold of 59.5 yielded high sensitivity (100%) but limited specificity (67%) for identifying RSA-defined resistance.
conclusionThese findings confirm the continued expansion of the PfK13 R561H lineage in Rwanda and provide a first ex vivo indication that the N490T variant confers an AR phenotype. While the eRRSA shows potential as a high-throughput screening tool for surveillance due to its high sensitivity, further refinement of recovery thresholds and clinical validation are required to improve its predictive specificity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.